The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Clinical validation – randomised trials and interventions

Leaders of work package 8: Gustav Smith and Andreas Edsfeldt

LUDC-IRC takes advantage of the accumulated expertise of investigators and resources available to conduct recall trials based on pathogenetically relevant biomarkers or genotypes or based upon subtype of diabetes.

Work package 8 has access to  unique, large-scale clinical cohorts that include patients with diabetes and diabetes-associated complications, such as the All New Diabetics In Scania (ANDIS) cohort. The large accessible cohorts from which participants can be recalled and the excellent metabolic research facilities makes it possible to perform studies to validate potential markers of disease progression or markers of response to treatment or other interventions. 


  • To provide a platform and accumulated expertise for proof of concept trials originated from discoveries within LUDC-IRC.
  • To provide a platform and accumulated expertise for prevention and intervention clinical trials, including evaluation of new therapies and life-style interventions.
  • To generate new samples for the discovery of dynamic biomarkers (i.e., a biomarker that captures the drug response and allows for accurate estimations of long-term drug efficacy).

Selected publications


Andreas Edsfeldt
Work Package Leader
Associate Professor of cardiovascular research at Lund University
+46 (0)763 50 15 16
andreas [dot] edsfeldt [at] med [dot] lu [dot] se

Gustav Smith
Work Package Leader
Professor of cardiology at University of Gothenburg
+46 (0)46 17 26 33
gustav [dot] smith [at] med [dot] lu [dot] se